Review



tgf β 1  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems tgf β 1
    Tgf β 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 41 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgf β 1/product/R&D Systems
    Average 94 stars, based on 41 article reviews
    tgf β 1 - by Bioz Stars, 2026-06
    94/100 stars

    Images



    Similar Products

    93
    Sino Biological recombinant proteins tgf beta 1 protein
    Recombinant Proteins Tgf Beta 1 Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant proteins tgf beta 1 protein/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    recombinant proteins tgf beta 1 protein - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    94
    R&D Systems tgf β 1
    Tgf β 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgf β 1/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    tgf β 1 - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    94
    R&D Systems tgf β
    NFIB transcriptionally inhibits CCL5 induction in HSCs. (A) A CCL5 promoter luciferase (−1000) was transfected to LX‐2 cells with increasing doses of NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (B) Hypergeometric optimization of motif enrichment analysis. (C) Truncated CCL5 promoter–luciferase constructs were transfected into LX‐2 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (D) LX‐2 cells were treated <t>with</t> <t>TGF‐β</t> (2 ng/mL) and harvested at the indicated time points. ChIP assays were performed with anti‐NFIB or IgG. N = 3. (E) Re‐ChIP assays were performed with the indicated antibodies. N = 3. (F) Wild‐type and mutated CCL5 promoter‐luciferase constructs were transfected into HEK293 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (G) The mRNA and protein levels of CCL5 were detected by PCR and ELISA. N = 3. LX‐2 cells were treated with recombinant CCL5 (20 ng/mL) for 24 h after NFIB overexpression. (H) The mRNA levels of Acta2, Postn , and NFIB in LX‐2 cells were measured by quantitative PCR. N = 3. (I) Boyden chamber transwell assay (100×). N = 3. (J) Cell proliferation was evaluated using EdU (200×). N = 3. (K) Collagen contraction assay. N = 3. Data are expressed as the mean±SD. * p < 0.05, two‐tailed Student's t ‐test.
    Tgf β, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgf β/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    tgf β - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    97
    R&D Systems recombinant human tgf β1 lap
    NFIB transcriptionally inhibits CCL5 induction in HSCs. (A) A CCL5 promoter luciferase (−1000) was transfected to LX‐2 cells with increasing doses of NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (B) Hypergeometric optimization of motif enrichment analysis. (C) Truncated CCL5 promoter–luciferase constructs were transfected into LX‐2 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (D) LX‐2 cells were treated <t>with</t> <t>TGF‐β</t> (2 ng/mL) and harvested at the indicated time points. ChIP assays were performed with anti‐NFIB or IgG. N = 3. (E) Re‐ChIP assays were performed with the indicated antibodies. N = 3. (F) Wild‐type and mutated CCL5 promoter‐luciferase constructs were transfected into HEK293 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (G) The mRNA and protein levels of CCL5 were detected by PCR and ELISA. N = 3. LX‐2 cells were treated with recombinant CCL5 (20 ng/mL) for 24 h after NFIB overexpression. (H) The mRNA levels of Acta2, Postn , and NFIB in LX‐2 cells were measured by quantitative PCR. N = 3. (I) Boyden chamber transwell assay (100×). N = 3. (J) Cell proliferation was evaluated using EdU (200×). N = 3. (K) Collagen contraction assay. N = 3. Data are expressed as the mean±SD. * p < 0.05, two‐tailed Student's t ‐test.
    Recombinant Human Tgf β1 Lap, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human tgf β1 lap/product/R&D Systems
    Average 97 stars, based on 1 article reviews
    recombinant human tgf β1 lap - by Bioz Stars, 2026-06
    97/100 stars
      Buy from Supplier

    93
    R&D Systems human lap
    NFIB transcriptionally inhibits CCL5 induction in HSCs. (A) A CCL5 promoter luciferase (−1000) was transfected to LX‐2 cells with increasing doses of NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (B) Hypergeometric optimization of motif enrichment analysis. (C) Truncated CCL5 promoter–luciferase constructs were transfected into LX‐2 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (D) LX‐2 cells were treated <t>with</t> <t>TGF‐β</t> (2 ng/mL) and harvested at the indicated time points. ChIP assays were performed with anti‐NFIB or IgG. N = 3. (E) Re‐ChIP assays were performed with the indicated antibodies. N = 3. (F) Wild‐type and mutated CCL5 promoter‐luciferase constructs were transfected into HEK293 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (G) The mRNA and protein levels of CCL5 were detected by PCR and ELISA. N = 3. LX‐2 cells were treated with recombinant CCL5 (20 ng/mL) for 24 h after NFIB overexpression. (H) The mRNA levels of Acta2, Postn , and NFIB in LX‐2 cells were measured by quantitative PCR. N = 3. (I) Boyden chamber transwell assay (100×). N = 3. (J) Cell proliferation was evaluated using EdU (200×). N = 3. (K) Collagen contraction assay. N = 3. Data are expressed as the mean±SD. * p < 0.05, two‐tailed Student's t ‐test.
    Human Lap, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human lap/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human lap - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    R&D Systems human tgfβ
    NFIB transcriptionally inhibits CCL5 induction in HSCs. (A) A CCL5 promoter luciferase (−1000) was transfected to LX‐2 cells with increasing doses of NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (B) Hypergeometric optimization of motif enrichment analysis. (C) Truncated CCL5 promoter–luciferase constructs were transfected into LX‐2 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (D) LX‐2 cells were treated <t>with</t> <t>TGF‐β</t> (2 ng/mL) and harvested at the indicated time points. ChIP assays were performed with anti‐NFIB or IgG. N = 3. (E) Re‐ChIP assays were performed with the indicated antibodies. N = 3. (F) Wild‐type and mutated CCL5 promoter‐luciferase constructs were transfected into HEK293 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (G) The mRNA and protein levels of CCL5 were detected by PCR and ELISA. N = 3. LX‐2 cells were treated with recombinant CCL5 (20 ng/mL) for 24 h after NFIB overexpression. (H) The mRNA levels of Acta2, Postn , and NFIB in LX‐2 cells were measured by quantitative PCR. N = 3. (I) Boyden chamber transwell assay (100×). N = 3. (J) Cell proliferation was evaluated using EdU (200×). N = 3. (K) Collagen contraction assay. N = 3. Data are expressed as the mean±SD. * p < 0.05, two‐tailed Student's t ‐test.
    Human Tgfβ, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human tgfβ/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human tgfβ - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    93
    Sino Biological recombinant tgf β1
    NFIB transcriptionally inhibits CCL5 induction in HSCs. (A) A CCL5 promoter luciferase (−1000) was transfected to LX‐2 cells with increasing doses of NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (B) Hypergeometric optimization of motif enrichment analysis. (C) Truncated CCL5 promoter–luciferase constructs were transfected into LX‐2 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (D) LX‐2 cells were treated <t>with</t> <t>TGF‐β</t> (2 ng/mL) and harvested at the indicated time points. ChIP assays were performed with anti‐NFIB or IgG. N = 3. (E) Re‐ChIP assays were performed with the indicated antibodies. N = 3. (F) Wild‐type and mutated CCL5 promoter‐luciferase constructs were transfected into HEK293 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (G) The mRNA and protein levels of CCL5 were detected by PCR and ELISA. N = 3. LX‐2 cells were treated with recombinant CCL5 (20 ng/mL) for 24 h after NFIB overexpression. (H) The mRNA levels of Acta2, Postn , and NFIB in LX‐2 cells were measured by quantitative PCR. N = 3. (I) Boyden chamber transwell assay (100×). N = 3. (J) Cell proliferation was evaluated using EdU (200×). N = 3. (K) Collagen contraction assay. N = 3. Data are expressed as the mean±SD. * p < 0.05, two‐tailed Student's t ‐test.
    Recombinant Tgf β1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant tgf β1/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    recombinant tgf β1 - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    Image Search Results


    NFIB transcriptionally inhibits CCL5 induction in HSCs. (A) A CCL5 promoter luciferase (−1000) was transfected to LX‐2 cells with increasing doses of NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (B) Hypergeometric optimization of motif enrichment analysis. (C) Truncated CCL5 promoter–luciferase constructs were transfected into LX‐2 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (D) LX‐2 cells were treated with TGF‐β (2 ng/mL) and harvested at the indicated time points. ChIP assays were performed with anti‐NFIB or IgG. N = 3. (E) Re‐ChIP assays were performed with the indicated antibodies. N = 3. (F) Wild‐type and mutated CCL5 promoter‐luciferase constructs were transfected into HEK293 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (G) The mRNA and protein levels of CCL5 were detected by PCR and ELISA. N = 3. LX‐2 cells were treated with recombinant CCL5 (20 ng/mL) for 24 h after NFIB overexpression. (H) The mRNA levels of Acta2, Postn , and NFIB in LX‐2 cells were measured by quantitative PCR. N = 3. (I) Boyden chamber transwell assay (100×). N = 3. (J) Cell proliferation was evaluated using EdU (200×). N = 3. (K) Collagen contraction assay. N = 3. Data are expressed as the mean±SD. * p < 0.05, two‐tailed Student's t ‐test.

    Journal: Advanced Science

    Article Title: Nuclear Factor I‐B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription

    doi: 10.1002/advs.202511311

    Figure Lengend Snippet: NFIB transcriptionally inhibits CCL5 induction in HSCs. (A) A CCL5 promoter luciferase (−1000) was transfected to LX‐2 cells with increasing doses of NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (B) Hypergeometric optimization of motif enrichment analysis. (C) Truncated CCL5 promoter–luciferase constructs were transfected into LX‐2 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (D) LX‐2 cells were treated with TGF‐β (2 ng/mL) and harvested at the indicated time points. ChIP assays were performed with anti‐NFIB or IgG. N = 3. (E) Re‐ChIP assays were performed with the indicated antibodies. N = 3. (F) Wild‐type and mutated CCL5 promoter‐luciferase constructs were transfected into HEK293 cells with or without NFIB. Luciferase activities were normalized by protein concentration and green fluorescent protein. N = 3. (G) The mRNA and protein levels of CCL5 were detected by PCR and ELISA. N = 3. LX‐2 cells were treated with recombinant CCL5 (20 ng/mL) for 24 h after NFIB overexpression. (H) The mRNA levels of Acta2, Postn , and NFIB in LX‐2 cells were measured by quantitative PCR. N = 3. (I) Boyden chamber transwell assay (100×). N = 3. (J) Cell proliferation was evaluated using EdU (200×). N = 3. (K) Collagen contraction assay. N = 3. Data are expressed as the mean±SD. * p < 0.05, two‐tailed Student's t ‐test.

    Article Snippet: Prior to TGF‐β (2 ng/mL; #246‐LP‐025; R&D System, Minneapolis, MN, USA) stimulation, LX‐2 cells were subjected to an overnight serum starvation, which imitated HSC activation in vitro [ ].

    Techniques: Luciferase, Transfection, Protein Concentration, Construct, Enzyme-linked Immunosorbent Assay, Recombinant, Over Expression, Real-time Polymerase Chain Reaction, Boyden Chamber Transwell Assay, Contraction Assay, Two Tailed Test

    Juglone attenuates HSC activation and MASH fibrosis. (A‐C) LX‐2 cells were subjected to TGF‐β1 (2 ng/mL) treatment for 24 h with or without juglone treatments (3, 10, or 30 µ m ). Then, all cells were harvested for studies as follows. (A) The mRNA levels of Acta2 and NFIB in LX‐2 cells were measured by qPCR. N = 3. (B) Collagen contraction assay. N = 3. (C) Boyden chamber transwell assay (100×). N = 3. (D–H) C57BL/6 mice were fed on an CDAHFD diet for 8 weeks, during which they concurrently received different doses of Juglone (0.25 and 1.0 mg/kg) via oral gavage. Hepatic profibrogenic genes in mouse liver tissues were examined using quantitative PCR (D) and Western blotting (E). N = 3–7. (F) Liver sections were stained with H&E (50×), picrosirius red (50×), Masson's (50×) and IHC (100×) (CD3, F4/80) staining. N = 7. (G) IF staining (50×) for 4‐HNE expression in liver tissues. N = 7. (H) Plasma AST and ALT levels. N = 7. (I) Hepatic hydroxyproline levels. N = 7. Data are expressed as the mean±SD. * p < 0.05, two‐tailed Student's t ‐test.

    Journal: Advanced Science

    Article Title: Nuclear Factor I‐B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription

    doi: 10.1002/advs.202511311

    Figure Lengend Snippet: Juglone attenuates HSC activation and MASH fibrosis. (A‐C) LX‐2 cells were subjected to TGF‐β1 (2 ng/mL) treatment for 24 h with or without juglone treatments (3, 10, or 30 µ m ). Then, all cells were harvested for studies as follows. (A) The mRNA levels of Acta2 and NFIB in LX‐2 cells were measured by qPCR. N = 3. (B) Collagen contraction assay. N = 3. (C) Boyden chamber transwell assay (100×). N = 3. (D–H) C57BL/6 mice were fed on an CDAHFD diet for 8 weeks, during which they concurrently received different doses of Juglone (0.25 and 1.0 mg/kg) via oral gavage. Hepatic profibrogenic genes in mouse liver tissues were examined using quantitative PCR (D) and Western blotting (E). N = 3–7. (F) Liver sections were stained with H&E (50×), picrosirius red (50×), Masson's (50×) and IHC (100×) (CD3, F4/80) staining. N = 7. (G) IF staining (50×) for 4‐HNE expression in liver tissues. N = 7. (H) Plasma AST and ALT levels. N = 7. (I) Hepatic hydroxyproline levels. N = 7. Data are expressed as the mean±SD. * p < 0.05, two‐tailed Student's t ‐test.

    Article Snippet: Prior to TGF‐β (2 ng/mL; #246‐LP‐025; R&D System, Minneapolis, MN, USA) stimulation, LX‐2 cells were subjected to an overnight serum starvation, which imitated HSC activation in vitro [ ].

    Techniques: Activation Assay, Contraction Assay, Boyden Chamber Transwell Assay, Real-time Polymerase Chain Reaction, Western Blot, Staining, Expressing, Clinical Proteomics, Two Tailed Test